📊 ENTX Key Takeaways
Is ENTX a Good Investment? Thesis Analysis
Entera Bio is a pre-revenue biotech company with minimal commercial traction (42K revenue) and severe cash burn of 5.5M annually in operating activities. With only 8.6M in cash and negative free cash flow of 5.6M, the company has less than 18 months of runway at current burn rates, creating significant going concern risk. The company lacks profitability, positive cash generation, and demonstrated commercial viability.
Why Buy ENTX? Key Strengths
- Strong liquidity position with 10.83x current ratio providing near-term operational flexibility
- Zero debt/equity ratio eliminates financial leverage risk and debt service obligations
- Substantial stockholders equity of 15.2M relative to liabilities suggests retained capital from financing
ENTX Investment Risks to Consider
- Critical cash runway of approximately 18 months at current burn rate with no profitable operations to offset losses
- Negligible revenue generation (42K) demonstrates complete lack of commercial market validation or product adoption
- Persistent operating losses of 8.5M with negative operating margin of -20207% indicates fundamental business model challenges
- Negative free cash flow of 5.6M indicates company is consuming capital faster than it can sustain without additional financing
- Pre-revenue biotech stage with high execution risk and dependence on future drug development success
Key Metrics to Watch
- Quarterly revenue growth and evidence of any commercial traction or clinical progress
- Cash burn rate and remaining cash runway to determine urgency of financing needs
- Operating cash flow trends and any movement toward sustainability
- Progress on pipeline development and clinical trial milestones
- Insider transaction patterns and insider confidence levels
ENTX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 10.83x current ratio provides a solid financial cushion.
ENTX Profitability Ratios
ENTX vs Healthcare Sector
How Entera Bio Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ENTX Overvalued or Undervalued?
Based on fundamental analysis, Entera Bio Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ENTX Balance Sheet & Liquidity
ENTX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Entera Bio Ltd.'s revenue has declined by 68% over the 5-year period, indicating business contraction. The most recent EPS of $0.31 reflects profitable operations.
ENTX Growth Metrics (YoY)
ENTX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$3.0M | $0.07 |
| Q2 2025 | N/A | -$2.1M | $0.06 |
| Q1 2025 | N/A | -$2.0M | $0.05 |
| Q3 2024 | N/A | -$2.4M | $0.08 |
| Q2 2024 | N/A | -$2.1M | $0.06 |
| Q3 2023 | N/A | -$2.4M | $0.08 |
| Q2 2023 | N/A | -$2.3M | $0.08 |
| Q1 2023 | N/A | -$2.2M | $0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ENTX Capital Allocation
ENTX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Entera Bio Ltd. (CIK: 0001638097)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENTX
What is the AI rating for ENTX?
Entera Bio Ltd. (ENTX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENTX's key strengths?
Claude: Strong liquidity position with 10.83x current ratio providing near-term operational flexibility. Zero debt/equity ratio eliminates financial leverage risk and debt service obligations.
What are the risks of investing in ENTX?
Claude: Critical cash runway of approximately 18 months at current burn rate with no profitable operations to offset losses. Negligible revenue generation (42K) demonstrates complete lack of commercial market validation or product adoption.
What is ENTX's revenue and growth?
Entera Bio Ltd. reported revenue of $42.0K.
Does ENTX pay dividends?
Entera Bio Ltd. does not currently pay dividends.
Where can I find ENTX SEC filings?
Official SEC filings for Entera Bio Ltd. (CIK: 0001638097) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENTX's EPS?
Entera Bio Ltd. has a diluted EPS of $0.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ENTX a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Entera Bio Ltd. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ENTX stock overvalued or undervalued?
Valuation metrics for ENTX: ROE of -55.3% (sector avg: 15%), net margin of -20,054.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ENTX stock in 2026?
Our dual AI analysis gives Entera Bio Ltd. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENTX's free cash flow?
Entera Bio Ltd.'s operating cash flow is $-5.5M, with capital expenditures of $80.0K. FCF margin is -13,373.8%.
How does ENTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -20,054.8% (avg: 12%), ROE -55.3% (avg: 15%), current ratio 10.83 (avg: 2).